ArticleACS medicinal chemistry letters2026
How Subtle Molecular Differences in the Morphinan Opioid Antagonists Affect Their Physicochemical and In Vitro ADME Properties.
Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naloxone, naltrexone and nalmefene are closely related morphinan antagonists with comparable affinities to the μ-opioid receptor (MOR) but markedly different pharmacokinetics (PK) and metabolic fate. In this study, we evaluated their pharmacologically-relevant molecular/physicochemical properties, PAMPA-BBB (Parallel Artificial Membrane Permeability Assay for the Blood-Brain Barrier) permeability and in vitro metabolic stability to determine how subtle structural differences influence ADME-relevant properties. Moreover, the pharmacologically-relevant properties of these three antagonists were compared with those of the best-known synthetic opioid agonist, fentanyl. We found that the methyl-cyclopropyl versus allyl head group, as well as the C6-carbonyl versus C6-ethenyl group, dramatically influence all the above-mentioned properties and help explain the in vivo observed differences between these antagonists. These results may support the rational design of new and improved opioid antagonists with optimized PK properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.